{"disease":{"id":"sintilimab","name":"sintilimab"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04982939","title":"Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":210,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT06459921","title":"Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT06413342","title":"Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":191,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT06714708","title":"Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":86,"lead_sponsor_name":"Anhui Provincial Cancer Hospital","has_results":false},{"nct_id":"NCT06342167","title":"Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT03936452","title":"Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05400070","title":"Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":45,"lead_sponsor_name":"Tang-Du Hospital","has_results":false},{"nct_id":"NCT05218148","title":"SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":44,"lead_sponsor_name":"Aiping Zhou","has_results":false},{"nct_id":"NCT05707819","title":"Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":43,"lead_sponsor_name":"Cancer Hospital of Guangxi Medical University","has_results":false},{"nct_id":"NCT04146831","title":"Sintilimab in FH-deficient Renal Cell Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":37,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT04618367","title":"HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04023916","title":"Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04271813","title":"Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Shanghai Changzheng Hospital","has_results":false},{"nct_id":"NCT06070636","title":"bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07416890","title":"Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT05105672","title":"A Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"The Affiliated Hospital of Xuzhou Medical University","has_results":false},{"nct_id":"NCT05810142","title":"Clinical Study on Third-line Treatment of Advanced Duodenal Adenocarcinoma by Fuquinitinib Combined With Sindillimab","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT06015035","title":"Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Tang-Du Hospital","has_results":false}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}